These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23548432)

  • 1. [Angiotensin II receptor antagonists in cardiology: course to organoprotection].
    Timofeeva NIu; Snetkova AA; Zadionchenko VS
    Kardiologiia; 2013; 53(3):88-93. PubMed ID: 23548432
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of the renin-angiotensin system in cardiovascular disease.
    Cohn JN
    Cardiovasc Drugs Ther; 2010 Aug; 24(4):341-4. PubMed ID: 20454841
    [No Abstract]   [Full Text] [Related]  

  • 3. Blockers of the renin-angiotensin-aldosterone system: almost, but not yet, an absolute weapon against cardiovascular and renal diseases!
    Waeber B
    J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):216. PubMed ID: 22389390
    [No Abstract]   [Full Text] [Related]  

  • 4. Less RAAS is more, or not.
    Shah NK; Choksi R; Epstein BJ
    Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1363-5. PubMed ID: 22059783
    [No Abstract]   [Full Text] [Related]  

  • 5. The evolution of angiotensin blockade in the management of cardiovascular disease.
    Nantel P; René de Cotret P
    Can J Cardiol; 2010 Dec; 26 Suppl E():7E-13E. PubMed ID: 21620285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic pathways in the RAS.
    Bader M; Santos RA; Unger T; Steckelings UM
    J Renin Angiotensin Aldosterone Syst; 2012 Dec; 13(4):505-8. PubMed ID: 23166114
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease.
    Abramov D; Carson PE
    J Renin Angiotensin Aldosterone Syst; 2012 Sep; 13(3):317-27. PubMed ID: 22610916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inflammation and atherosclerosis: the role of Renin-Angiotensin system and its inhibition].
    Partigulova AS; Naumov VG
    Kardiologiia; 2010; 50(10):50-5. PubMed ID: 21118180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence.
    Unger T; Culman J; Gohlke P
    J Hypertens Suppl; 1998 Sep; 16(7):S3-9. PubMed ID: 9855025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II receptors and drug discovery in cardiovascular disease.
    Dasgupta C; Zhang L
    Drug Discov Today; 2011 Jan; 16(1-2):22-34. PubMed ID: 21147255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
    Ramahi TM
    Postgrad Med; 2001 Apr; 109(4):115-22; quiz 9. PubMed ID: 11317462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving landscape of RAAS inhibition: from ACE inhibitors to ARBs, to DRIs and beyond.
    Epstein BJ; Leonard PT; Shah NK
    Expert Rev Cardiovasc Ther; 2012 Jun; 10(6):713-25. PubMed ID: 22894628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New therapeutic perspectives associated with the introduction of angiotensin II receptor antagonists].
    Peczkowska M; Kabat M; Janaszek-Sitkowska H
    Pol Arch Med Wewn; 1997 Apr; 97(4):379-90. PubMed ID: 9411416
    [No Abstract]   [Full Text] [Related]  

  • 14. Blockade of the renin-angiotensin system.
    Cheung BM
    Hong Kong Med J; 2002 Jun; 8(3):185-91. PubMed ID: 12055364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with angiotensin II antagonists in hypertensive patients.
    Waeber B; Burnier M; Nussberger J; Brunner HR
    Clin Exp Pharmacol Physiol; 1996 Sep; 23 Suppl 3():S142-6. PubMed ID: 21143288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cardiovascular outcomes in chronic dialysis patients: a population-based cohort study.
    Bajaj RR; Wald R; Hackam DG; Gomes T; Perl J; Juurlink DN; Manno M; Garg AX; Kitchlu A; Mamdani MM; Yan AT
    Arch Intern Med; 2012 Apr; 172(7):591-3. PubMed ID: 22493468
    [No Abstract]   [Full Text] [Related]  

  • 17. Renin-angiotensin system blockade: Its contribution and controversy.
    Miyajima A; Kosaka T; Kikuchi E; Oya M
    Int J Urol; 2015 Aug; 22(8):721-30. PubMed ID: 26032599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the renin-angiotensin system in liver fibrosis.
    Sancho-Bru P; Ginès P
    Hepatol Int; 2016 Sep; 10(5):730-2. PubMed ID: 27246697
    [No Abstract]   [Full Text] [Related]  

  • 19. Renin-angiotensin system blockade and reduction of cardiovascular risk: future perspectives.
    de la Sierra A
    Expert Rev Cardiovasc Ther; 2011 Dec; 9(12):1585-91. PubMed ID: 22103877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reviewing the future of renin-angiotensin system blockade: the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the prevention of atrial fibrillation.
    Ducharme A; Schiffrin EL
    Can J Cardiol; 2010 Dec; 26 Suppl E():21E-23E. PubMed ID: 21620287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.